U.S. Markets close in 3 hrs 24 mins
  • S&P 500

    4,523.82
    -53.28 (-1.16%)
     
  • Dow 30

    34,486.58
    -153.21 (-0.44%)
     
  • Nasdaq

    15,009.38
    -371.94 (-2.42%)
     
  • Russell 2000

    2,161.19
    -45.14 (-2.05%)
     
  • Crude Oil

    67.03
    +0.53 (+0.80%)
     
  • Gold

    1,781.90
    +19.20 (+1.09%)
     
  • Silver

    22.43
    +0.11 (+0.51%)
     
  • EUR/USD

    1.1315
    +0.0009 (+0.0792%)
     
  • 10-Yr Bond

    1.3850
    -0.0630 (-4.35%)
     
  • Vix

    30.97
    +3.02 (+10.81%)
     
  • GBP/USD

    1.3239
    -0.0064 (-0.4779%)
     
  • USD/JPY

    112.8180
    -0.3910 (-0.3454%)
     
  • BTC-USD

    54,824.97
    -1,803.20 (-3.18%)
     
  • CMC Crypto 200

    1,390.77
    -50.99 (-3.54%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients with the KRAS-G12C mutation.

  • The decision was based on preliminary results from the Phase 1/2 KRYSTAL-01 trial in patients with advanced NSCLC whose cancer had progressed following prior treatment with immunotherapy or chemotherapy.

  • According to data presented in October, 45% of patients saw an objective response.

  • Those numbers come from a pooled data set of 51 patients who received 600 mg doses in Mirati's Phase 1/1b and 2. 42% achieved a partial response, and 51% saw stable disease as of the August cut-off.

  • In a pooled set of 110 patients (including those with colorectal cancer and other tumors), 30% suffered severe/life-threatening treatment-related side effects, the most frequent being increased ALT and AST.

  • Two patients died due to treatment-related events, including one with pneumonitis and one with cardiac failure.

  • "We look forward to submitting a New Drug Application for adagrasib in the second half of this year and further advancing adagrasib across a broad development plan to improve clinical outcomes in patients with KRASG12C mutated cancers," CEO Charles Baum said in a statement.

  • Price Action: MRTX shares are up 3.75% at $168.55 in the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.